daytrading march 28 pre-market, page-7

PXS - short term star?

May 2011, knock back from Europe, pxs dropped 75% to 71c then bounced almost 100% to $1.39 in the next two days.
PXS lost 75% following the negative news of US approval from $1.25 to 32c.

The big differences currently are:

1. Pxs has cash on hand close to $80m + $20m from NovaQuest on pxs' option, close to current market cap.
2. Bronchitol approved and is selling in Europe, UK, Australia
3. Achieved Milestone in Phase 3 Trial for Bronchiectasis which targets a much bigger market.